Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2024, 5, 10]], 'date-time': '2024-05-10T01:10:18Z', 'timestamp': 1715303418873}, 'posted': {'date-parts': [[2020, 11, 16]]}, 'group-title': 'In Review', 'reference-count': 0, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2020, 11, 16]], 'date-time': '2020-11-16T00:00:00Z', 'timestamp': 1605484800000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 10, 30]]}, 'abstract': '<title>Abstract</title>\n' ' <p><bold>Background:</bold> Up-to-date, there is no recognized effective treatment or ' 'vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective ' 'therapies. This study aims to evaluate the anti-parasitic medication efficacy "Ivermectin" ' 'plus standard care ((Azithromycin, vitamin C, Zinc, Lactoferrin &amp; Acetylcystein &amp; ' 'prophylactic or therapeutic anticoagulation if D-dimer &gt; 1000)) in the treatment of ' 'mild/moderate and severely ill cases with COVID 19 infection, as well as prophylaxis of ' 'health care and/ or household contacts in comparison to the ' '<italic>Hydroxychloroquine</italic> plus standard treatment.<bold>Subject and methods:</bold> ' '600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health care and household ' 'contacts distributed over 6 groups; <italic>Group I</italic><bold>:</bold> 100 patients with ' 'mild/moderate COVID-19 infection received a 4-days course of Ivermectin plus standard of ' 'care; <italic>Group II:</italic> 100 patients with mild/moderate COVID-19 infection received ' 'hydroxychloroquine plus standard of care; <italic>Group III:</italic> 100 patients with ' 'severe COVID-19 infection received Ivermectin plus standard of care; <italic>Group ' 'IV</italic>: 100 patients with Severe COVID-19 infection received hydroxychloroquine plus ' 'standard of care. Routine laboratory investigations and RT-PCR, were reported before and ' 'after initiation of treatment. <italic>Group V stick to PPE plus Ivermectin 400mcg / kg on ' 'empty stomach to be repeated after one week, and group VI stick to PPE only (personal ' 'protective equipment) .Both groups V&amp;VI were followed for two weeks ' '..</italic><bold>Results:</bold> Patients received ivermectin reported substantial recovery ' 'of laboratory investigations; and significant reduction in RT-PCR conversion days. A ' 'substantial improvement and reduction in mortality rate in Ivermectin treated groups; group I ' '(mild/moderate cases), (99%, and 0.0%, respectively) and group III (severe cases), (94%, and ' '2.0% respectively) versus hydroxychloroquine plus standard care treated groups; group II ' '(mild/moderate cases), (74% and 4%, respectively) and group IV (severe cases) (50% and 20%, ' 'respectively). Ivermectin had significantly reduced the incidence of infection in health care ' 'and household contacts up to 2% compared to 10% in non ivermectin group when used as a ' 'prophylaxis.<bold>Conclusion:</bold><italic> </italic>Addition of Ivermectin to standard care ' 'is very effective drug for treatment of COVID-19 patients with significant reduction in ' 'mortality compared to Hydroxychloroquine plus standard treatment only. Early use of ' 'Ivermectin is very useful for controlling COVID 19 infections; prophylaxis and improving ' 'cytokines storm</p>', 'DOI': '10.21203/rs.3.rs-100956/v2', 'type': 'posted-content', 'created': { 'date-parts': [[2020, 11, 16]], 'date-time': '2020-11-16T23:00:32Z', 'timestamp': 1605567632000}, 'source': 'Crossref', 'is-referenced-by-count': 16, 'title': 'WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic', 'prefix': '10.21203', 'author': [ { 'given': 'Ahmed', 'family': 'Elgazzar', 'sequence': 'first', 'affiliation': [{'name': 'Banha University'}]}, { 'given': 'Basma', 'family': 'Hany', 'sequence': 'additional', 'affiliation': [ { 'name': 'Community Medicine Department, Faculty of Medicine, Benha ' 'University, Egypt.'}]}, { 'given': 'Shaimaa Abo', 'family': 'Youssef', 'sequence': 'additional', 'affiliation': [{'name': 'Banha University'}]}, { 'given': 'Mohy', 'family': 'Hafez', 'sequence': 'additional', 'affiliation': [{'name': 'Benha Faculty of medicine'}]}, { 'given': 'Hany', 'family': 'Moussa', 'sequence': 'additional', 'affiliation': [{'name': 'Kafr Elsheikh University, Faculty of medicine, Chest department'}]}, { 'given': 'Abdelaziz', 'family': 'eltaweel', 'sequence': 'additional', 'affiliation': [{'name': 'Benha University'}]}], 'member': '8761', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-100956/v2', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-100956/v2.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 5, 10]], 'date-time': '2024-05-10T00:57:45Z', 'timestamp': 1715302665000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-100956/v2'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 11, 16]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-100956/v2', 'relation': { 'is-version-of': [ { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-100956/v1', 'asserted-by': 'subject'}, { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-100956/v3', 'asserted-by': 'subject'}, { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-100956/v4', 'asserted-by': 'subject'}]}, 'subject': [], 'published': {'date-parts': [[2020, 11, 16]]}, 'subtype': 'preprint'}